A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Rezivertinib (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Beta Pharma
Most Recent Events
- 07 Aug 2024 Planned End Date changed from 29 Feb 2024 to 30 Dec 2025.
- 01 Sep 2023 Planned End Date changed from 1 Oct 2023 to 29 Feb 2024.
- 01 Sep 2023 Planned primary completion date changed from 1 Oct 2022 to 31 Dec 2023.